These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35547159)

  • 1. Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures.
    Wang Z; Zhang T; Wu W; Wu L; Li J; Huang B; Liang Y; Li Y; Li P; Li K; Wang W; Guo R; Wang Q
    Front Bioeng Biotechnol; 2022; 10():883791. PubMed ID: 35547159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
    Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
    ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.
    Wei IH; Shi Y; Jiang H; Kumar-Sinha C; Chinnaiyan AM
    Neoplasia; 2014 Nov; 16(11):918-27. PubMed ID: 25425966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin.
    Liu H; Qiu C; Wang B; Bing P; Tian G; Zhang X; Ma J; He B; Yang J
    Front Cell Dev Biol; 2021; 9():619330. PubMed ID: 34012960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Learning-Based Pan-Cancer Classification Model Reveals Tissue-of-Origin Specific Gene Expression Signatures.
    Divate M; Tyagi A; Richard DJ; Prasad PA; Gowda H; Nagaraj SH
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational concordance analysis provides supportive information for double cancer diagnosis.
    Hatakeyama K; Nagashima T; Notsu A; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Kenmotsu H; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
    BMC Cancer; 2021 Feb; 21(1):181. PubMed ID: 33607950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
    Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
    Szymanski JJ; Sundby RT; Jones PA; Srihari D; Earland N; Harris PK; Feng W; Qaium F; Lei H; Roberts D; Landeau M; Bell J; Huang Y; Hoffman L; Spencer M; Spraker MB; Ding L; Widemann BC; Shern JF; Hirbe AC; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003734. PubMed ID: 34464388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs.
    Tomeva E; Switzeny OJ; Heitzinger C; Hippe B; Haslberger AG
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIREVAT: finding reliable variants without artifacts in human cancer samples using etiologically relevant mutational signatures.
    Kim H; Lee AJ; Lee J; Chun H; Ju YS; Hong D
    Genome Med; 2019 Dec; 11(1):81. PubMed ID: 31847917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.
    Liu W; Vivian CJ; Brinker AE; Hampton KR; Lianidou E; Welch DR
    Cancer Microenviron; 2014 Dec; 7(3):117-31. PubMed ID: 24938990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis.
    Ding W; Chen G; Shi T
    Epigenetics; 2019 Jan; 14(1):67-80. PubMed ID: 30696380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.
    Bao L; Messer K; Schwab R; Harismendy O; Pu M; Crain B; Yost S; Frazer KA; Rana B; Hasteh F; Wallace A; Parker BA
    PLoS One; 2015; 10(11):e0142487. PubMed ID: 26554380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DiaDeL: An Accurate Deep Learning-Based Model With Mutational Signatures for Predicting Metastasis Stage and Cancer Types.
    Abdollahi S; Lin PC; Chiang JH
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(3):1336-1343. PubMed ID: 34570707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.
    Herrmann S; Zhan T; Betge J; Rauscher B; Belle S; Gutting T; Schulte N; Jesenofsky R; Härtel N; Gaiser T; Hofheinz RD; Ebert MP; Boutros M
    Mol Oncol; 2019 Aug; 13(8):1669-1683. PubMed ID: 31254442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservation of immune gene signatures in solid tumors and prognostic implications.
    Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
    BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG-Islands as Markers for Liquid Biopsies of Cancer Patients.
    Sprang M; Paret C; Faber J
    Cells; 2020 Aug; 9(8):. PubMed ID: 32752173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.